FINANCIAL STATEMENTS 127 17 TRAdE ANd oTHER pAyAblES 2008 2007 2006 $m $m $m Current liabilities Trade payables 3,903 3,497 3,482 Value added and payroll taxes and social security 371 434 280 Other payables 1,026 865 1,166 Accruals 1,878 2,172 1,367 7,178 6,968 6,295 Non-current liabilities Other payables 149 229 254 Included in other payables are amounts totalling $227m 2007: $209m: 2006: $241m to meet insurance obligations of the Groups insurance subsidiaries.
18 pRovISIoNS FoR lIAbIlITIES ANd CHARgES Employee Other Severance Environmental benefits provisions Total $m $m $m $m $m At 1 January 2006 62 68 122 102 354 Charge credit for year 1 56 36 4 87 On acquisition of subsidiary 20 20 Cash paid 36 29 36 5 106 Exchange and other movements 6 13 18 11 At 31 December 2006 31 95 109 131 366 Charge for year 620 48 4 58 730 Cash paid 25 32 23 25 105 Exchange and other movements 17 10 2 29 At 31 December 2007 643 111 100 166 1,020 Charge credit for year 469 37 23 164 647 Cash paid 405 39 1 12 457 Exchange and other movements 88 21 8 9 68 At 31 December 2008 619 130 84 309 1,142 2008 2007 2006 $m $m $m Due within one year 600 387 39 Due after more than one year 542 633 327 1,142 1,020 366 AstraZeneca is undergoing a worldwide restructuring initiative which involves rationalisation of the Global Supply Chain, European Sales and Marketing, Information Services and Business Support infrastructure and Research and Development.
Employee costs in connection with the initiatives are recognised in severance provisions.
This is a three-year programme expected to be substantially completed by the end of 2010.
Details of the environmental provisions are provided in Note 25.
Employee benefit provisions include the executive deferred bonus plan and other employee benefit provisions.
Further details are included in Note 24.
Other provisions comprise various amounts relating to specific legal and constructive obligations and disputes.
No provision has been released or applied for any purpose other than that for which it was established.
ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008
